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Abstract
Purpose Many women with an elevated risk of hereditary
breast and ovarian cancer have previously tested negative
for pathogenic mutations in BRCA1 and BRCA2. Among
them, a subset has hereditary susceptibility to cancer and
requires further testing. We sought to identify specific
groups who remain at high risk and evaluate whether they
should be offered multi-gene panel testing.
Methods We tested 300 women on a multi-gene panel who
were previously enrolled in a long-term study at UCSF. As
part of their long-term care, all previously tested negative for
mutations in BRCA1 and BRCA2 either by limited or com-
prehensive sequencing. Additionally, they met one of the
following criteria: (i) personal history of bilateral breast
cancer, (ii) personal history of breast cancer and a first or
second degree relative with ovarian cancer, and (iii) personal
history of ovarian, fallopian tube, or peritoneal carcinoma.
Results Across the three groups, 26 women (9%) had a
total of 28 pathogenic mutations associated with hereditary
cancer susceptibility, and 23 women (8%) had mutations in
genes other than BRCA1 and BRCA2. Ashkenazi Jewish
and Hispanic women had elevated pathogenic mutation
rates. In addition, two women harbored pathogenic muta-
tions in more than one hereditary predisposition gene.
Conclusions Among women at high risk of breast and
ovarian cancer who have previously tested negative for
pathogenic BRCA1 and BRCA2 mutations, we identified
three groups of women who should be considered for
subsequent multi-gene panel testing. The identification of
women with multiple pathogenic mutations has important
implications for family testing.
Keywords Hereditary cancer  Panel testing  BRCA1 
BRCA2  Breast cancer  Ovarian cancer
Introduction
The advent of next-generation sequencing (NGS) technology
has revolutionized the clinical approach to genetic testing
across many areas of medicine including medical oncology.
Instead of single gene testing, interrogating a panel of multiple
genes provides clinicians information about one or more dis-
orders in a single test [1–4]. Additionally, new methods of
identifying large rearrangements using NGS data have allowed
for more comprehensive testing [5–7]. A number of studies
have recently investigated the clinical validity of comprehen-
sivemulti-gene panels in the context of clinicalmanagement of
breast and ovarian cancer [8–11]. These studies are clarifying
which genes to include for each disease and how to counsel
patients and their families regarding penetrance, screening,
surveillance, and risk-reducing options.
Over one million people in the U.S. alone are believed
to have had prior testing for pathogenic BRCA1 and
BRCA2 mutations, but not a broader panel [12]. The great
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majority has received a negative test result, yet some still
harbor an undiscovered pathogenic BRCA1 or BRCA2
mutation (due to limited sequencing) or a pathogenic
mutation in another cancer susceptibility gene. Multiple
studies have shown that 3–4% of high-risk individuals have
germline pathogenic mutations in cancer risk genes other
than BRCA1 and BRCA2, including ATM, CHEK2, PALB2,
PTEN, TP53, and others [4, 13]. With the emergence of
broader multi-gene panels, re-testing these individuals will
be required to identify those carrying previously unidenti-
fied mutations. However, no clear guidelines exist to sug-
gest which individuals should be offered additional testing
using such panels. In this study, we sought to identify
characteristics among individuals previously negative for
pathogenic BRCA1 and BRCA2 mutations who may benefit
from multi-gene panel testing.
Methods
Study cohort
The UCSF-CGPP, previously named Cancer Risk Program,
was founded in 1996 in order to provide genetic risk
assessments for patients with personal and family histories
of cancer. In 1997, the UCSF-CGPP received institutional
review board approval for a long-term follow-up program
aimed at promoting research efforts associated with hered-
itary cancer risk. The great majority of patients participating
in the program banked one clinical sample for further family
testing and one research sample. All patients who banked
samples received genetic counseling and risk assessment. As
of April, 2016, 7213 women had agreed to participate in this
follow-up program and 4892 (68%) banked a DNA sample
for research purposes. Of these, 1281 women (26%) had a
personal history of breast or ovarian cancer, previously
tested negative for pathogenic BRCA1 or BRCA2 mutations
by one of several methods, and met NCCN criteria for
BRCA1 and BRCA2 testing [14]. From this pool, we ran-
domly selected de-identified and blinded samples which
satisfied inclusion criteria listed in Table 1: bilateral breast
cancer (n = 97), breast cancer and family history of ovarian
cancer (n = 104), and ovarian cancer (n = 99). History of
disease was confirmed by a breast oncologist via pathology
review and/or medical record review (see supplementary
eMethods). At the time of this study, 32 patients (10.7%)
were confirmed deceased by family member notification or
electronic medical record review.
Gene selection
The Color panel is comprised of 19 genes clinically rele-
vant to breast and ovarian cancer: ATM, BARD1, BRCA1,
BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2,
MSH6, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D,
STK11, and TP53. Genes were selected based on published
evidence that women who have pathogenic mutations in
these genes are at increased risk of developing breast and/
or ovarian cancer (see supplementary eTable 2). Prelimi-
nary studies have suggested that due to overlapping phe-
notypes, multi-gene panel testing will find a significant
number of mutations that would be missed when testing for
Hereditary Breast and Ovarian Cancer syndrome, Lynch
syndrome, Cowden syndrome, Li-Fraumeni syndrome, or
other hereditary cancer syndromes individually [15, 16].
For this reason, a single panel was created covering all of
these syndromes rather than individual syndrome-specific
panels.
Gene sequencing
A total of 400 nanograms of banked genomic DNA were
sheared on a Covaris LE-220 sonicator (Woburn, MA) to
obtain 300 base pair (bp) mean size fragments. Genomic
DNA was quantified and assessed for quality using Drop-
Sense UV spectroscopy as well as Biotium AccuBlue
Fluorescence Assay (Ghent, Belgium; Hayward CA). The
entire coding region, exon–intron boundaries (±20 bp),
and other regions containing known pathogenic mutations
were targeted and captured using Agilent SureSelect
Table 1 Study criteria
Inclusion criteria Exclusion criteria
1. Female patient affected with 1. Previous clinical or research
gene panel testing or whole
exome sequencing
a. Bilateral breast cancer
b. Breast cancer and a first-
degree or second-degree
relative with ovarian cancer
c. Ovarian cancer (ovarian,
fallopian tube cancer, or
primary peritoneal
carcinomatosis)
2. Banked DNA sample for
research
2. Previously identified
pathogenic or likely pathogenic
mutation in any gene
3. Met current (v1.2015) NCCN
high-risk criteria
3. Adopted
4. Previously negative BRCA1/
BRCA2 testing (e.g., Ashkenazi
Jewish founder mutations,
BRCA1/BRCA2 full
sequencing, 5-site
rearrangements, and/or deletion
duplication)
4.\10 mcg DNA
Legend Inclusion and exclusion criteria used in this study
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custom RNA probes (Santa Clara, CA). Sequencing
libraries were constructed following the Agilent SureS-
electXT protocol and were quantified using the KAPA
Biosystems Library Quantification Kit (Woburn, MA).
These steps were performed in an automated fashion using
the Hamilton automated liquid-handling platform. Quanti-
fied libraries were sequenced on the Illumina NextSeq NGS
platform (San Diego, CA) using the 2 9 150 bp configu-
ration. Bioinformatics and data quality control followed the
Genome Analysis Toolkit best practices (Broad Institute,
Cambridge, MA), with additional algorithms to detect
larger deletions and duplications. PMS2 exons 12–15 were
excluded from analysis because of high homology to a
known pseudogene.
Multi-gene panel validation
As part of this study, we validated the Color panel on 200
UCSF-CGPP patient samples harboring 159 BRCA1 or
BRCA2 mutations and several mutations in additional
genes associated with hereditary cancer. In this study, we
validated the 200 samples using the Color multi-gene panel
test prior to sequencing the 300 samples from our study
cohort. The Color test correctly identified all previously
observed clinically actionable mutations (supplementary
eTable 3). In addition, four samples had two pathogenic
mutations, the second of which was not identified by other
laboratories in each case.
Variant classification
Sequence variant classification as pathogenic, likely
pathogenic, variant of uncertain significance (VUS), likely
benign and benign was performed according to the
American College of Medical Genetics and Genomics
(ACMG) sequence variant interpretation guidelines [17].
All classifications were ultimately evaluated by a board-
certified pathologist or medical geneticist. Likely benign
and benign variants were not clinically reported. All vari-
ants classified as pathogenic, likely pathogenic, and VUS
were confirmed via a secondary technique. Sanger
sequencing was used to confirm single nucleotide variants
(SNVs), and small insertions and deletions (indels), while
larger deletions and duplications were confirmed via array
comparative genomic hybridization (aCGH) or multiplex
ligation-dependent probe amplification (MLPA).
Results
Patient demographics and cancer history
The study cohort consisted of 300 women who enrolled in
UCSF-CGPP between 1999 and 2014 and satisfied the
criteria described in Table 1. The majority of participants
(n = 195, 65%) was Caucasian with a large proportion
reporting Ashkenazi Jewish ancestry (n = 52, 17%). The
rest of the cohort self-identified as Asian (n = 29, 10%),
Hispanic (n = 22, 7%), unknown (n = 19, 6%), mixed
racial background (n = 13, 4%), African (n = 10, 3%),
Pacific Islander (n = 9, 3%), or Native American (n = 1,
0.3%) (Table 2).
Pathogenic mutations
Of the 300 high-risk women who had previously tested
negative for BRCA1 and BRCA2 pathogenic mutations, 26
women had a total of 28 pathogenic mutations in at least
Table 2 Demographics of the study population
Personal history of
bilateral breast cancer
Personal history of breast
cancer, relative with
ovarian cancer
Personal history
of ovarian cancer
Cohort
Patients (n) 97 104 99 300
Mean age at first diagnosis 50 (28–72) 48 (23–77) 54 (19–80) 51 (19–80)
Race/ethnicity
African 3% 4% 3% 3%
Ashkenazi 21% 16% 14% 17%
Asian 10% 8% 11% 10%
Caucasian 39% 55% 52% 49%
Hispanic 6% 8% 8% 7%
Mixed 4% 4% 5% 4%
Native American 0% 0% 1% 0.3%
Pacific Islands 2% 4% 3% 3%
Unknown 14% 2% 3% 6%
Legend Demographics reported by patients to genetic counselors as part of the UCSF-CGPP study
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one of the 19 genes sequenced, including three pathogenic
BRCA1 mutations that were not observed by previous, less
comprehensive testing (Table 3a–c). The cumulative inci-
dence of mutations in this cohort was 8.7% (n = 26) and
was consistent (8–9%) across the three different high-risk
groups. We observed two mutations in each of two women
with a personal history of ovarian cancer (Table 3) and in
four women in our validation set (Table 4).
Personal history of bilateral breast cancer
A total of 99 women in the study cohort had a personal
history of bilateral breast cancer or multiple breast cancers
with at least one in the contralateral breast. The average
age at diagnosis of the first breast cancer was 50, consistent
with the average age for the overall cohort. We detected
pathogenic mutations in nine of the 99 women in this group
involving the ATM, BRCA1, CDH1, and CHEK2 genes, all
of which have been associated with an increased risk of
bilateral breast cancer in the previous studies [18–22].
There were a disproportionately large number of CHEK2
c.1100delC mutations which have been postulated to be
enriched in bilateral breast cancer cases [22, 23]. Of note,
one large BRCA1 deletion common in the Hispanic
population was observed in a woman who previously
received negative test results for pathogenic BRCA1 and
BRCA2 mutations (Table 3). Investigation of her previous
testing revealed that large deletions and duplications had
not been assayed.
Table 3 Mutations identified in our three study cohorts
Personal history Gene Pathogenic mutation(s) Number of patients
Bilateral breast cancer ATM c.378delT 1
Bilateral breast cancer BRCA1 deletion of exons 8–11 (deletion of exons 9–12) 1
Bilateral breast cancer CDH1 c.1137G[A 1
Bilateral breast cancer CHEK2 c.1100delC 5
Bilateral breast cancer CHEK2 c.470T[C 1
Breast cancer, relative with ovarian cancer ATM c.742C[T 1
Breast cancer, relative with ovarian cancer BRCA1 c.2125_2126insAGT (2244ins3) 1
Breast cancer, relative with ovarian cancer CHEK2 c.1100delC 2
Breast cancer, relative with ovarian cancer PALB2 c.172_175delTTGT 1
Breast cancer, relative with ovarian cancer PALB2 c.2257C[T 1
Breast cancer, relative with ovarian cancer PALB2 c.3323delA 1
Breast cancer, relative with ovarian cancer RAD51D c.270_271insAT, c.269_270dupAT 1
Ovarian cancer ATM c.2T[C 1
Ovarian cancer ATM c.5065C[T 1
Ovarian cancer ATM &
PALB2
c.901?1G[A
c.2167_2168delAT
1
Ovarian cancer BRCA1 c.5095C[T (R1699 W) 1
Ovarian cancer CHEK2 c.1283C[T 1
Ovarian cancer CHEK2 &
RAD51C
c.1100delC
c.397C[T
1
Ovarian cancer MSH6 c.3438?1G[C 1
Ovarian cancer NBN c.1397?1delG 1
Ovarian cancer PALB2 c.2457delA 1
Legend Pathogenic variants found using the Color panel in our study cohort
Table 4 Validation samples with more than one pathogenic mutation
Gene Pathogenic mutations Number
of patients
BARD1 & BRCA1 c.1996C[T (Q666*)
c.1687C[T (Q563X)
1
BRCA1 & BRCA1 deletion of exons 7–9, and part of
exon 10 (deletion of exons 8–10,
and part of exon 11)
c.2101A[T (K701X)
1
BRCA2 & CHEK2 deletion of exon 3
c.499G[A
1
PALB2 & PMS2 c.172_175delTTGT
c.400C[T (R134*)
1
Total patients 4
Legend Summarizes women in the validation set with more than one
pathogenic mutation identified (complete list in supplementary
eTable 3)
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Personal history of breast cancer and family history
of ovarian cancer
A total of 104 women in the study cohort had a personal
history of breast cancer and a family history of ovarian
cancer. The average age at diagnosis was 48. Eight of 104
women had pathogenic mutations, one of which was a
previously undetected pathogenic BRCA1 mutation in a
Hispanic woman who had limited mutation testing
(Table 3). Most pathogenic mutations were in genes with
an established breast cancer risk (ATM, BRCA1, CHEK2,
and PALB2). Interestingly, an additional mutation was
detected in RAD51D, which may be associated with
increased risk of breast cancer and is associated with
increased risk of ovarian cancer [11, 24, 25].
Personal history of ovarian, fallopian tube cancer,
or peritoneal carcinomatosis
A total of 97 women in the study cohort had a personal
history of ovarian, fallopian tube cancer, or peritoneal car-
cinomatosis. The average age at diagnosis of cancer was 54.
Nine of 97women had pathogenicmutations. Twowomen in
this group had two pathogenic mutations each, in two dif-
ferent genes: one had pathogenic mutations in CHEK2 and
RAD51C, and the other had pathogenic mutations in ATM
and PALB2. Pathogenic mutations were observed in several
genes with well-established ovarian cancer risk: MSH6,
NBN, RAD51C, and one mutation in BRCA1 that was pre-
viously undetected due to limited testing. We also observed
pathogenic mutations in several genes that have not tradi-
tionally been associatedwith increased risk of ovarian cancer
(PALB2, ATM, and CHEK2).
Discussion
Considerations for panel testing
Today, genetic testing for Hereditary Breast Ovarian
Cancer syndrome has moved from testing of the BRCA1
and BRCA2 genes to broader panel testing. Here we
focused on clinical considerations for panel testing in
women who had previously tested negative for BRCA1 and
BRCA2 mutations. We studied three such groups:
(i) women with a personal history of bilateral breast cancer,
(ii) women with a personal history of breast cancer and a
first-degree or second-degree relative with ovarian cancer,
and (iii) women with a personal history of ovarian, fal-
lopian tube, or peritoneal carcinoma. From our study of
these groups, three criteria for re-testing emerged. First,
history of breast and ovarian cancer consistent with any of
the groups enumerated above suggests an elevated risk of
hereditary cancer and multi-gene panel testing for addi-
tional susceptibility genes should be considered. Second,
individuals who have previously received limited BRCA1
and BRCA2 gene testing may still harbor a genetic risk of
breast and/or ovarian cancer and should be considered for
multi-gene panel testing including large rearrangement
testing. Third, the presence of individuals with multiple
pathogenic mutations in both cohort samples and validation
samples, consistent with the previous studies [9], suggests
that comprehensive multi-gene panel testing could supplant
targeted testing for single known familial mutations.
History of cancer
Personal history of breast cancer, with and without a family
history of ovarian cancer, was the primary criteria used to
select individuals for this study from among all those who
had previously tested negative for BRCA1 and BRCA2
mutations. We observed an 8–9% pathogenic mutation rate
(Table 3) including previously missed BRCA1 mutations,
and a 7–8% pathogenic rate not including BRCA1 muta-
tions. This rate is two to three times the rate of pathogenic
mutations previously reported in these genes among
women with breast cancer or among individuals with sig-
nificant family history of breast cancer alone (3–4%)
[4, 13], indicating that this group is enriched for pathogenic
mutations associated with hereditary breast and ovarian
cancer, hereditary diffuse gastric cancer, or Lynch syn-
drome genes compared to high-risk individuals in general.
The high pathogenic mutation rate in this cohort suggests
that all individuals who meet criteria for inclusion in one of
our subgroups would benefit from multi-gene panel testing.
In addition to these groups, there likely exist broader
groups of the previously tested individuals who harbor
pathogenic mutations that warrant re-testing using multi-
gene panels. For instance, the high rate of mutations we
observed in women who met NCCN criteria and also had
personal history of ovarian cancer (8%) could indicate that
all women with ovarian cancer may benefit from multi-
gene panel testing. Supporting this hypothesis, previous
studies have demonstrated elevated rates of pathogenic
mutations in genes other than BRCA1 and BRCA2 (6–7%)
[3, 8] among women with ovarian cancer. The NCCN and
the Society of Gynecologic Oncology both recommend
BRCA1 and BRCA2 genetic testing for all women with
ovarian cancer, and parallel re-testing of all of these
women using multi-gene panels may be warranted due to
the observed mutation rates in this group.
Limited genetic testing and ethnicity
In the study cohort, three types of limited BRCA1 and
BRCA2 testing were previously used by other laboratories:
Breast Cancer Res Treat (2017) 163:383–390 387
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Ashkenazi founder mutation testing, Hispanic founder
mutation testing, and gene testing without analysis of large
deletions and duplications. Multi-gene panel testing by
Color panel identified three mutations in the BRCA1 gene
(12% of mutations in the study cohort) that were not
identified by the previous limited testing. One pathogenic
BRCA1 mutation was identified in a woman who had
testing limited to Ashkenazi Jewish and Hispanic muta-
tions [26] due to her combined ancestry; one mutation was
identified in a woman who had testing of only Hispanic
mutations; and one mutation was identified in a woman
who had previous full sequencing of BRCA1 and BRCA2
without assessment of large deletions and duplications.
All three of these mutations were missed in individuals
of partial or full Hispanic origin. Given the increase in
frequency of large deletions and duplications in the His-
panic population [27–29] (20% of identified mutations in
high-risk Hispanic populations) and the relatively recent
lack of testing available for such variants [26, 30, 31],
missed mutations in these genes may be more common in
the high-risk Hispanic population than in other ethnicities.
Additionally, elevated rates of pathogenic mutations in
other genes were observed in certain ethnicities, particu-
larly among Ashkenazi Jewish and Hispanic individuals
(12 and 18%, respectively, see Table 5). It appears that
limited BRCA1 and BRCA2 testing based on ethnicity may
miss a significant number of clinically actionable muta-
tions. There may be a larger range of mutations expressed
in a single ethnicity than previously observed [4, 32], and
this effect may be exacerbated by reported or unreported
mixed ethnic backgrounds. Because of the potential to miss
such mutations, re-testing of individuals who previously
had limited BRCA1 and BRCA2 testing should be consid-
ered, particularly in ethnicities with elevated risk or if a
strong suspicion for hereditary cancer otherwise remains.
Further, with individuals of unclear ancestry, unknown
ancestry, or mixed-race, multi-gene panel testing could be
considered as the primary test for identification of muta-
tions associated with hereditary cancer susceptibility.
Family testing of mutation carriers
Following identification of a pathogenic mutation, a car-
rier’s family members are typically offered targeted single-
site testing (or cascade testing) specific to the identified
pathogenic mutation in order to determine each member’s
risk of hereditary cancer. The identification of pathogenic
mutations in two different genes in a single individual,
present in both our validation set and study cohort, indi-
cates that such testing may be inadequate to clinically
determine the risk of hereditary cancer for two reasons:
1. If a mutation carrier has two mutations and those
mutations are expected to segregate separately, family
members of the carrier who test negative by single-site
testing for one of the mutations may still carry the
other.
2. If a carrier is discovered with a mutation in a single
gene, family members may carry a different mutation
(in a different gene) inherited separately, whether that
member tests positive or negative for the previously
discovered family mutation.
Pathogenic mutations in multiple genes in the same indi-
vidual have been observed in approximately 3% of patients
in larger cohorts who received breast, ovarian, colon, and
general hereditary cancer risk testing [9], similar to the
1–2% of multiple mutation carriers identified within our
study. These findings indicate that individuals with multi-
ple mutations are identified with some frequency and their
family members may be falsely reassured based on single-
site testing alone. Because of this issue, multi-gene panel
testing should be considered to identify these missed
pathogenic mutations, providing a more accurate assess-
ment of hereditary cancer risk in known mutation carriers
and their family members.
Testing options
Despite negative BRCA1 and BRCA2 test results, in certain
cases, clinicians often remain suspicious of another
hereditary cancer syndrome due to the family history of
cancer. Nevertheless, efforts to obtain additional genetic
testing are often limited due to lack of insurance coverage,
resulting in prohibitively high costs for patients. With the
rise of more affordable testing options, clinicians and their
Table 5 Distribution of mutations within each ethnicity
Personal
history of
bilateral breast
cancer (%)
Personal
history of
breast cancer,
relative with
ovarian
cancer (%)
Personal
history
of
ovarian
cancer
(%)
Cohort
(%)
Race/ethnicity
African 0 25 0 10
Ashkenazi 10 6 21 12
Asian 0 13 9 7
Caucasian 16 5 4 8
Hispanic 17 13 25 18
Pacific
Islands
0 25 20 15
Group
cumulative
9 9 8 8.7
Legend Pathogenic variants identified in each reported ethnicity
within each group and in the whole cohort
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patients now have greater access to multi-gene panel test-
ing, both as a follow-on test for those with previously
incomplete testing and as a first-line approach.
Limitations and future directions
This study was enriched for individuals at high risk of
breast and ovarian cancer as defined by the NCCN criteria.
Consequently, this study cohort likely represents individ-
uals with higher than average breast and ovarian cancer
risks and is not representative of those patients with mild to
moderate cancer risks nor is it representative of the general
population. Larger cohorts will be required to determine
more accurate rates of pathogenic mutations in women
with previously negative hereditary cancer testing.
The study population represented a cohort of primarily
Caucasian women, which is not generalizable to the pop-
ulation at large. Furthermore, a large proportion (17%) of
patients in the cohort were of Ashkenazi Jewish descent.
While other studies have found no increased detection rate
despite enrichment for Ashkenazi Jewish participants
[4, 13], the high proportion of Ashkenazi Jewish women in
our study may have altered the number or type of patho-
genic variants detected.
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